Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC vs IV Granisetron PK in Cancer
NCT00450853Phase 2Completed
- Sponsor
- Universidad de Navarra
- Start
- Apr 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of granisetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Universidad de Navarra. Primary endpoint: Bioavailability at 6 weeks. Started Apr 2005; status: completed.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00450853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450853.